Equities

WAVE Life Sciences Ltd

WAVE Life Sciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)15.89
  • Today's Change-0.55 / -3.35%
  • Shares traded1.90m
  • 1 Year change+202.67%
  • Beta-1.1960
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform7
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Wave Life Sciences Ltd have a median target of 22.00, with a high estimate of 36.00 and a low estimate of 15.00. The median estimate represents a 33.82% increase from the last price of 16.44.
High119.0%36.00
Med33.8%22.00
Low-8.8%15.00

Earnings history & estimates in USD

On Nov 12, 2024, Wave Life Sciences Ltd reported 3rd quarter 2024 losses of -0.47 per share.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate-50.72%
Wave Life Sciences Ltd reported annual 2023 losses of -0.540 per share on Mar 06, 2024.
Average growth rate+39.56%
More ▼

Revenue history & estimates in USD

Wave Life Sciences Ltd. had revenues for the full year 2023 of 113.31m. This was 3,005.10% above the prior year's results.
Average growth rate+760.91%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.